Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
We added to our position in Regeneron Pharmaceuticals, a biotech company in the Health Care sector. The stock ranks...
— Josef Lakonishok, Menno Vermeulen, Puneet Mansharamani, Greg Sleight, Guy Lakonishok, Gal Skarishevsky
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals ($REGN), representing 4.7% of the fund's portfolio, is a leading biotechnology company that discovers, invents, and commercializes innovative medicines for serious diseases. The manager maintains...
Regeneron Pharmaceuticals is a leading biotechnology firm that invents, develops, and commercializes medicines for serious conditions, particularly in immunology and oncology. Regeneron represents 6.5%...
More institutional theses from Harbor Mid Cap Value Fund